Reversing Temozolomide Resistance in Glioblastoma Based on Cuproptosis‐Mediated Positive Feedback Loop
Advanced Science · 2026-10 · 13 (57)
DOI: 10.1002/advs.76677 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 20.07.2026. Verfasst von Wenjie Feng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, P. R. China. Hauptthemen laut MEDLINE: Cuproptosis, Temozolomide, Drug Resistance, Neoplasm, Glioblastoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Postdoctoral Fellowship Program of CPSF, Science and Technology Development Program of Jilin Province.
Abstract (Originalsprache)
Glioblastoma (GBM), one of the most lethal human cancers, faces a major therapeutic challenge due to drug resistance. Temozolomide (TMZ), a standard first‐line drug for clinical GBM treatment, benefits only a subset of patients, leaving an urgent need for strategies that can restore its efficacy. Herein, we propose that cuproptosis, a recently identified regulated cell death (RCD), is capable of reversing TMZ resistance in GBM. We design copper‐TMZ (Cu‐TMZ) prodrugs, assembled via the coordination of Cu 2+ with TMZ and, in optimized formulations, co‐loaded with metformin (MET) as an AMPK activator, to exploit cuproptosis for overcoming TMZ resistance. Upon glutathione‐triggered disassembly, the prodrugs release Cu + and TMZ, inducing mitochondrial proteotoxic stress and initiating a self‐amplifying cuproptosis loop characterized by ATP depletion, AMPK‐p53 activation, and glycolysis inhibition. Beyond self‐reinforcement, cuproptosis directly potentiates TMZ activity by suppressing drug efflux, impairing DNA repair, and aggravating metabolic and redox stress. Both in vitro and in vivo experiments demonstrate that Cu‐TMZ/MET prodrugs markedly restore TMZ responsiveness and suppress TMZ‐resistant GBM progression. More broadly, this study illustrates how RCD pathways can be engineered into therapeutics to convert drug resistance into vulnerability, highlighting a generalizable strategy for improving the efficacy of frontline chemotherapy in otherwise intractable cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, P. R. China.
- Department of Neurosurgery, The First Hospital of Jilin University, Changchun, P. R. China.
- State Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, P. R. China.
Förderung
- National Natural Science Foundation of China
- Postdoctoral Fellowship Program of CPSF
- Science and Technology Development Program of Jilin Province
- MOST
- Ministry of Science and Technology of the People's Republic of China
Zitieren
APA
Feng, W., Yang, R., Weng, C., Li, C., Shi, W., Chen, Y., Yang, Y., Liu, Y., Ge, P., & Zhang, H. (2026). Reversing Temozolomide Resistance in Glioblastoma Based on Cuproptosis‐Mediated Positive Feedback Loop. Advanced Science, 13(57). https://doi.org/10.1002/advs.76677
Vancouver
Feng W, Yang R, Weng C, Li C, Shi W, Chen Y, et al. Reversing Temozolomide Resistance in Glioblastoma Based on Cuproptosis‐Mediated Positive Feedback Loop. Advanced Science. 2026;13(57). doi:10.1002/advs.76677
BibTeX
@article{Feng2026,
author = {Feng, Wenjie and Yang, Rui and Weng, Chang and Li, Chen and Shi, Wanrui and Chen, Yang and Yang, Yang and Liu, Yi and Ge, Pengfei and Zhang, Hao},
title = {Reversing Temozolomide Resistance in Glioblastoma Based on Cuproptosis‐Mediated Positive Feedback Loop},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {57},
doi = {10.1002/advs.76677}
}
EUVIMED